[276 Pages Report] The global swine respiratory diseases treatment market size is expected to reach a valuation of USD 2.0 Billion by the end of 2022, and further expand at a CAGR of 6.3% from 2022 to 2032. The market is likely to reach a valuation of USD 3.6 Billion by the end of 2032. Mycoplasma under the causative agent segment is leading the swine respiratory diseases treatment market and it held a share of about 35.2% in 2021.
Based on the severity and duration of the observable condition, swine respiratory disorders can be grouped into two main categories: those that affect a significant number of pigs and may be hazardous but only last a short while, and those that affect a large number of pigs for an extended period of time. Costs of diseases in the first category are limited rather than continuing.
Swine influenza, classical swine fever, pneumonic pseudorabies, porcine circovirus-associated illness, and pig reproductive and respiratory syndrome (PRRS) are categorized among them. Although pathogenic viruses may survive in a herd, outbreaks of overt sickness are usually self-limiting. Mycoplasma pneumonia and pleuropneumonia are the most common syndromes in the second category like rhinitis atrophic.
| Attributes | Key Statistics |
|---|---|
| Global Swine Respiratory Diseases Treatment Market Estimated Size (2022E) | USD 1,978.1 Million |
| Projected Market Valuation (2032F) | USD 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Collective Value Share: Top 5 Countries | 61.4% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global swine respiratory diseases treatment market held approximately 1.9% of the overall veterinary services market, which was worth ~USD 99.5 Billion in 2021. Sales of swine respiratory disease treatment services expanded at a CAGR of 6.1% from 2012 to 2021.
Demand for swine respiratory disease treatment options is on the rise due to the increasing number of foodborne and zoonotic diseases. According to the most recent annual report on food diseases issued by the European Food Safety Authority (EFSA) and the European Center for Disease Prevention and Control (ECDC) in February 2021, foodborne infections are on the rise compared to the previous year, with pathogenic bacteria such as campylobacter spp. being the most common cause.
Around 5175 food outbreaks were documented, accounting for 49463 clinical cases, 3859 hospital admissions, and 60 deaths (+50% compared to the previous year). Salmonella, norovirus, escherichia coli, yersinia enterocolitica, cryptosporidium parvum, and campylobacter jejuni were the most common etiological agents found, while the most common causes of infection were eggs & egg products, bakery items, hog meat, processed foods, water, crustaceans, and vegetables.
Additionally, the market for swine respiratory diseases treatment is anticipated to grow in terms of research & development (R&D) spending and revenue owing to external partnerships and strategic alliances between industries and academia. For instance, in September 2022, Zoetis acquired NewMetrica, which had developed cutting-edge digital instruments in the form of standardized questionnaires that were intended to evaluate health-related quality of life (HRQL) in nonverbal species, as a strategic addition to their companion animal portfolio. Thus, owing to the aforementioned factors, the global swine respiratory diseases treatment market is expected to grow at a CAGR of 6.3% during the forecast period from 2022 to 2032.
Government Investments to Boost Access to Advanced Treatment Will Aid Growth
The market is likely to provide an opportunistic perspective owing to various initiatives by governments in emerging countries. Government bodies are investing significantly in healthcare infrastructure modernization, which is expected to bolster access to advanced healthcare services. This factor is set to fuel demand for upgraded technologies, thereby creating an appealing opportunity in the global swine respiratory diseases treatment market.
In high-income economies like the UK and the USA, there will likely be a greater emphasis on innovation to prevent zoonotic diseases combined with biotechnology breakthroughs, which will create a favorable environment for the development of veterinary therapeutics. These methods include systems biology, synthetic biology, and next-generation sequencing among others. Additionally, maintaining investments in multidisciplinary research may accelerate the time to market for new products and enhance the efficiency of therapy development.
The large market potential for veterinary therapeutics is expected to emerge throughout the forecast period as a result of growing economies in emerging markets like Latin America and Asia Pacific. The potential that these markets present are due to a large number of factors, including the increasing cost of living for the urban middle-class population in these regions, which further surges per-capita meat consumption and fuels the need for more effective livestock farming.
Stringent regulations put forward by the USA Food & Drug Administration (FDA) to limit the use of antibiotics for farm animals and the rising cost of innovation-dampening Research and Development investments can hamper the market in the forecast period. If antibiotics are administered to livestock that is raised for food such as swine and other animals, they may lose their efficacy in humans. Antibiotic-resistant bacteria known as superbugs are on the rise as a result of the widespread use of antibiotics in both humans and animals.
The cost of drug innovation has been increasing, as compared to earlier years. The trend is similar for animal healthcare. This is primarily attributed to a limited scope of research for newer diseases in livestock animals. Due to this, drug makers are investing more in the development of innovative drugs for diseases, which are already highly mature. This further raises Research and Development spending and dampens return on investment (ROI). These factors cumulatively propose a negative effect on developmental growth in the swine respiratory diseases treatment market.
Rising Prevalence of Zoonotic Diseases in the USA to Push Growth by 2032
The USA dominates the North American swine respiratory diseases treatment market and held a total share of about 52.9% in 2021. It is expected to continue to experience the same growth rate throughout the forecast period.
Owing to the increased swine respiratory diseases related deaths, high consumption of animal meats, and growing prevalence of zoonotic diseases, producers or manufacturers operating in the market are presented with new growth opportunities to develop unique preventive measures, which would further boost the market in the USA
Surging Need for H1N1 Influenza Treatment in Canada to Drive the Industry Forward
Canada held approximately 47.1% of the share in the North American swine respiratory diseases treatment market in 2021 and it is expected to showcase growth at a lucrative CAGR of 6.7% during the forecast period.
Influenza viruses are frequently found in pigs, who can be infected by humans, birds, or other pigs. Predominant influenza subtypes prevalent in pigs in Canada are H1N1, H1N2, and h4N2. Swine influenza viruses do not generally infect humans; however, these viruses have occasionally infected humans.
Cases mainly emerge because of direct or indirect contact with pigs in numerous settings such as farms or agricultural fairs. The Canadian Food Inspection Agency (CFIA) advises veterinarians and producers to maintain strict biosecurity measures to reduce any hazards to human or animal health.
Rising Cases of Swine Fever in Pigs to Propel Growth in Germany by 2032
Germany is set to exhibit a CAGR of nearly 5.8% in the Europe swine respiratory diseases treatment market during the forecast period. Germany is becoming increasingly popular when it comes to health and innovation. With the surging prevalence of influenza A (H1), as well as increasing surveillance and management measures of the disease implemented by the World Health Organization (WHO), the demand for swine respiratory disease treatment options will grow at a rapid pace.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Mycoplasma-based Swine Diseases to Exhibit High Growth in the Upcoming Decade
Mycoplasma-based causative agents are expected to witness high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 35.2% in 2021. The major pathogen of enzootic pneumonia, a chronic respiratory disease in pigs, is mycoplasma hyopneumoniae. Infections caused by mycoplasma hyopneumoniae are common in practically all swine production locations, which leads to huge economic losses due to increased medicine consumption and lower pig performance.
Common Swine Diseases Are Expected to Be Treated with Antibiotics
The drugs segment is expected to create high growth at a CAGR of 6.1% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 63.8% in 2021. Antibiotic use during all stages of growth enhances the efficiency and efficacy of body weight gain, lowers death rates & comorbidities, reduces subclinical disease, and improves pig health.
Veterans Prefer Oral Route of Administration to Treat Swine Fever Disease
The oral route of administration is expected to exhibit high growth at a CAGR of 6.3% by the end of the forecast period. The segment held a swine respiratory diseases treatment market share of about 86.3% in 2021. The oral route of administration is the most common form of medication administration in farm animals. Medications are mixed with animal feed for ease of ingestion, which would push the segment.
Veterinary Hospitals to Offer Advanced Treatment Options for Swine Bacterial Diseases
Veterinary hospitals held the highest swine respiratory diseases treatment market share of 37.0% in 2021. Pigs are considered to be better medical research subjects than mice as their size, physiology, and genetic makeup are more similar to humans.
With several competitors in the swine respiratory diseases treatment market, the overall industry is highly fragmented. To meet rising consumer demand and expand their customer base, these companies are implementing various methods such as mergers & acquisitions, partnerships & collaborations, and new product launches.
Some of the recent developments in the swine respiratory diseases treatment market are given below:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | USD 1,978.1 Million |
| Projected Market Valuation (2032) | USD 3,649.5 Million |
| Value-based CAGR (2022 to 2032) | 6.3% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | Value (USD Million) |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
| Key Market Segments Covered | Causative Agent, Treatment, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Zoetis; Bayer AG; Boehringer Ingelheim GmbH; Elanco Animal Health (Sub. Eli Lilly); Virbac; Norbrook; Ceva Santé Animale; Intervet Inc., (Sub. Merck & Co. Inc.); Vetoquinol SA; Bimeda Inc.; Kyoritsu Seiyaku Corporation; HIPRA; Agrilabs, Inc.; Ashish LifeSciences Ltd.; Cipla Pharmaceuticals.; Thermo Fisher Scientific Inc.; Huvepharma |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The global swine respiratory diseases treatment market was worth USD 1,852.0 Million in 2021 and is set to expand 1.8x over the next ten years.
The swine respiratory diseases treatment market is expected to reach USD 3,649.5 Million by the end of 2032, with sales revenue set to register a 6.3% CAGR.
Emergence of biologics & specialty care, growing awareness & affordability of therapeutics for livestock, and shifting distribution of drugs from traditional channels are some of the key trends in the swine respiratory diseases treatment market.
The USA, Canada, China, the Philippines, and South Korea are expected to drive demand in the swine respiratory diseases treatment market.
North America is one of the key regions, with the USA accounting for about 52.9% of the region’s swine respiratory diseases treatment market in the year 2021.
The swine respiratory disease treatment market in Japan is expected to register growth at a CAGR of 5.2% over the next ten years.
The swine respiratory disease treatment market in Germany is expected to register growth at a CAGR of 5.8% over the next ten years.
China, the USA, and the Philippines are the key producers of swine respiratory diseases treatment
Zoetis, Bayer AG, Boehringer Ingelheim GmbH, Elanco Animal Health (Sub. Eli Lilly), Virbac, Norbrook, Ceva Santé Animale, Intervet Inc. (Sub. Merck & Co. Inc.), Vetoquinol SA, Bimeda, Inc., Kyoritsu Seiyaku Corporation, HIPRA, Agrilabs, Inc., Ashish LifeSciences Ltd., Cipla Pharmaceuticals., Thermo Fisher Scientific Inc., and Huvepharma, are some of the key players in the swine respiratory diseases treatment market.
The global swine respiratory disease treatment market in South Korea is expected to register growth at a CAGR of 6.1% over the next ten years.
| Estimated Size, 2024 | USD 9,433.9 million |
|---|---|
| Projected Size, 2034 | USD 15,632.4 million |
| Value-based CAGR (2024 to 2034) | 5.2% |
| Estimated Market Size (2024E) | USD 19,442.9 million |
|---|---|
| Projected Market Value (2034F) | USD 33,211.3 million |
| Value-based CAGR (2024 to 2034) | 5.5% |
| Market Valuation (2023) | USD 40.9 billion |
|---|---|
| Market Valuation (2033) | USD 62.3 billion |
| Market CAGR (2023 to 2033) | 4.3% |
Explore Animal Health Therapeutics Insights
View Reports
Swine Respiratory Diseases Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
